Merck’s nine-valent HPV vaccine approved for marketing in China for male indications

April 15, 2025 Source: drugdu 78

On April 14, MerckAnnounced that Gardasil® 9 [9-valent human papillomavirus vaccine (crysogenyces cerevisiae)] (hereinafter referred to as "9-valent HPV vaccine") has been approved for marketing by the National Medical Products Administration for multiple new indications, and is suitable for males aged 16 to 26. This approval makes Gardasil® 9 the first and currently the only 9-valent HPV vaccine approved in China for males and females of appropriate age.